NYSE - Nasdaq Real Time Price USD

Novo Nordisk A/S (NVO)

Compare
87.37
-0.28
(-0.32%)
At close: December 27 at 4:00:02 PM EST
87.29
-0.08
(-0.09%)
After hours: December 27 at 7:59:41 PM EST
Loading Chart for NVO
DELL
  • Previous Close 87.65
  • Open 87.73
  • Bid 87.22 x 1300
  • Ask 87.36 x 800
  • Day's Range 87.02 - 88.77
  • 52 Week Range 81.50 - 148.15
  • Volume 6,057,926
  • Avg. Volume 6,288,090
  • Market Cap (intraday) 386.417B
  • Beta (5Y Monthly) 0.17
  • PE Ratio (TTM) 29.62
  • EPS (TTM) 2.95
  • Earnings Date Feb 5, 2025
  • Forward Dividend & Yield 1.45 (1.66%)
  • Ex-Dividend Date Aug 16, 2024
  • 1y Target Est 122.18

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

www.novonordisk.com

71,880

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVO

View More

Performance Overview: NVO

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVO
14.62%
OMX Copenhagen 25 Index
4.44%

1-Year Return

NVO
13.98%
OMX Copenhagen 25 Index
0.00%

3-Year Return

NVO
67.50%
OMX Copenhagen 25 Index
9.83%

5-Year Return

NVO
221.34%
OMX Copenhagen 25 Index
0.00%

Compare To: NVO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVO

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    394.52B

  • Enterprise Value

    392.02B

  • Trailing P/E

    29.58

  • Forward P/E

    22.47

  • PEG Ratio (5yr expected)

    1.31

  • Price/Sales (ttm)

    10.35

  • Price/Book (mrq)

    23.11

  • Enterprise Value/Revenue

    10.37

  • Enterprise Value/EBITDA

    20.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    35.01%

  • Return on Assets (ttm)

    21.47%

  • Return on Equity (ttm)

    88.73%

  • Revenue (ttm)

    270.58B

  • Net Income Avi to Common (ttm)

    94.72B

  • Diluted EPS (ttm)

    2.95

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    74.88B

  • Total Debt/Equity (mrq)

    47.27%

  • Levered Free Cash Flow (ttm)

    46.04B

Research Analysis: NVO

View More

People Also Watch